Vertex Pharmaceuticals

Vertex Pharmaceuticals is a biotechnology company that develops and commercializes medicines for serious diseases. Its core business focuses on cystic fibrosis treatments, with additional products for sickle cell disease, beta thalassemia and acute pain. Its expanding portfolio and drug development pipeline are key areas analysts evaluate.

Vertex Pharmaceuticals 是一家生物技术公司，专注于开发和商业化治疗严重疾病的药物。其核心业务是囊性纤维化治疗药物，同时也提供用于治疗镰状细胞病、β 地中海贫血和急性疼痛的产品。其不断扩大的产品组合及新药研发管线是分析师重点评估的领域。

Every figure on this page is tipranks’s, read on 2026-10-26 and linked below.

SmartChecker Vertex Pharmaceuticals Forecast

The forecast in short

tipranks records 24 analyst ratings on Vertex Pharmaceuticals and summarises them as “Strong Buy”. Their average 12-month price target is USD 589.45 (12.51% Upside). Its tipranks score is 8 out of 10 — Outperform. These are tipranks’s figures as SmartChecker read them on 2026-10-26, not SmartChecker’s own view, and nothing here is advice to buy or sell.

Market cap

USD 132.80 B

≈ Maybank x 4

Share price

USD 523.93

≈ RM 2139.94

#163World ranking

tipranks score

Outperform

8

Analyst ratings

Strong Buy

  • Buy21 88%
  • Hold3 13%
  • Sell0 0%

tipranks’s own summary of the 24 ratings above.

12 months price forecast

USD 589.45 12.51% Upside

USD 398.19 USD 495.94 USD 593.69 USD 691.44Past 12 months 12 months forecast High USD 667 Average USD 589.45 Low USD 4422025-10 2026-10

As tipranks publishes it. SmartChecker has not recalculated any of it.

Analyst profiles. Who made each call, and when.

AnalystFromPositionTarget priceDated
Michael YeeUBSBuyUSD 6152026-10-24
Geoff MeachamCitiBuyUSD 5852026-10-19
Tazeen AhmadBank of America SecuritiesBuyUSD 6672026-10-16
Mohit BansalWells FargoBuyUSD 5502026-10-15
Evan SeigermanBMO CapitalBuyUSD 6002026-10-12
Brian AbrahamsRBC CapitalBuyUSD 5762026-10-08
Terence FlynnMorgan StanleyBuyUSD 6652026-10-07
Jeffrey WalchBernsteinBuyUSD 6082026-09-25
Eliana MerleBarclaysBuyUSD 6172026-09-23
Danielle BrillTruist FinancialBuyN/A2026-09-23
Whitney IjemCanaccord GenuityHoldUSD 4422026-09-23
Louise ChenScotiabankBuyUSD 5582026-09-23
Akash TewariJefferiesBuyUSD 6402026-09-23
Paul MatteisStifel NicolausHoldN/A2026-09-22
Salveen RichterGoldman SachsBuyUSD 6532026-09-22
Andrew FeinH.C. WainwrightBuyUSD 6412026-09-22
Myles MinterWilliam BlairBuyN/A2026-09-22
Jessica FyeJ.P. MorganBuyUSD 5602026-09-11
Naz RahmanMaxim GroupBuyUSD 5752026-08-05
Phil NadeauTD CowenBuyUSD 5502026-08-04
Carter GouldCantor FitzgeraldBuyUSD 5952026-08-04
Joseph StringerNeedhamHoldN/A2026-08-04
Cory KasimovEvercore ISIBuyUSD 5352026-08-04
Andy ChenWolfe ResearchBuyUSD 5572026-08-03
Brian SkorneyRobert W. BairdSellUSD 3502026-07-07
Unknown AnalystRaymond JamesHoldN/A2026-06-24
Unknown AnalystGuggenheimBuyUSD 5462026-06-02
Hans EngelErste GroupHoldN/A2026-05-05
Nico ChenDBSBuyUSD 5402026-01-19
David RisingerLeerink PartnersBuyUSD 5252025-12-29
Show moreShow less

Investment Strengths

High-quality profitability and cash generation

Vertex combines substantial revenue with unusually strong margins and cash conversion, giving it internal funding capacity for research, launches and business development. This financial strength can support investment through development cycles while reducing reliance on external financing over the next several quarters.

Durable cystic fibrosis franchise growth

The CF franchise continues to expand through uptake of ALYFTREK, supporting recurring demand from patients using chronic therapies. Growth in the established franchise provides a durable commercial base and creates resources to fund Vertex’s newer launches and pipeline programs.

Pipeline diversification and launch execution

Progress across cell therapy, pain, renal disease and other clinical programs reduces reliance on a single future product while broadening Vertex’s potential commercial base. Continued launches and advancing studies create multiple avenues for growth beyond its historical CF concentration.

People also ask

What is the 12-month price target for Vertex Pharmaceuticals (VRTX)?

tipranks publishes an average 12-month price target of USD 589.45 (12.51% Upside), as SmartChecker read it on 2026-10-26. The highest target is USD 667 and the lowest is USD 442. A price target is an analyst’s estimate of where a share might trade, not a promise, and SmartChecker gives no investment advice.

See tipranks’s own page ↗
How many analysts cover Vertex Pharmaceuticals (VRTX)?

tipranks records 24 analyst ratings: 21 buy, 3 hold and 0 sell, which it summarises as “Strong Buy”, as SmartChecker read it on 2026-10-26.

See tipranks’s own page ↗
What is the tipranks score for Vertex Pharmaceuticals (VRTX)?

tipranks scores it 8 out of 10 and calls that “Outperform”, as SmartChecker read it on 2026-10-26. The score is tipranks’s, not SmartChecker’s, and SmartChecker does not rate listed shares.

See tipranks’s own page ↗
Is this SmartChecker’s own forecast for Vertex Pharmaceuticals?

No. Every figure on this page is published by tipranks, copied on 2026-10-26 with a link to the original, and not recalculated. SmartChecker assesses financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.

See tipranks’s own page ↗

Member reviews. Members’ own ratings and words, not SmartChecker’s rating.

These ratings and words are written by SmartChecker members and published immediately without administrator approval. SmartChecker does not rate listed companies: a rating here belongs to whoever wrote it, it counts towards no score of ours, and nothing in it is advice.

Disclaimer

SmartChecker provides informational and financial market news only and does not provide investment, financial or legal advice.

tipranks — Vertex Pharmaceuticals (VRTX)